Recombinant multi-species SETD1B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SETD1B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
SET1B is a component of a histone methyltransferase complex that produces trimethylated histone H3 at Lys4 (Lee et al., 2007 [PubMed 17355966]).[supplied by OMIM, Mar 2008]
The Alternative Names of target: SETD1B,Histone-lysine N-methyltransferase SETD1B,Lysine N-methyltransferase 2G, SET domain-containing protein 1B (hSET1B),KMT2G,Set1B,IDDSELD

Target products collectionGo to SETD1B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP2909-Ab-1/ GM-Tg-hg-IP2909-Ab-2 Human SETD1B protein Human
GM-Tg-rg-IP2909-Ab-1/ GM-Tg-rg-IP2909-Ab-2 Rat SETD1B protein Rat
GM-Tg-mg-IP2909-Ab-1/ GM-Tg-mg-IP2909-Ab-2 Mouse SETD1B protein Mouse
GM-Tg-cynog-IP2909-Ab-1/ GM-Tg-cynog-IP2909-Ab-2 Cynomolgus/Rhesus macaque SETD1B monoclonal antibody Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP2909-Ab-1/ GM-Tg-felg-IP2909-Ab-2 Feline SETD1B protein Feline
GM-Tg-cang-IP2909-Ab-1/ GM-Tg-cang-IP2909-Ab-2 Canine SETD1B protein Canine
GM-Tg-bovg-IP2909-Ab-1/ GM-Tg-bovg-IP2909-Ab-2 Bovine SETD1B protein Bovine
GM-Tg-equg-IP2909-Ab-1/ GM-Tg-equg-IP2909-Ab-2 Equine SETD1B protein Equine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP2909-Ab-1/ GM-Tg-hg-IP2909-Ab-2; GM-Tg-rg-IP2909-Ab-1/ GM-Tg-rg-IP2909-Ab-2;
GM-Tg-mg-IP2909-Ab-1/ GM-Tg-mg-IP2909-Ab-2; GM-Tg-cynog-IP2909-Ab-1/ GM-Tg-cynog-IP2909-Ab-2;
GM-Tg-felg-IP2909-Ab-1/ GM-Tg-felg-IP2909-Ab-2; GM-Tg-cang-IP2909-Ab-1/ GM-Tg-cang-IP2909-Ab-2;
GM-Tg-bovg-IP2909-Ab-1/ GM-Tg-bovg-IP2909-Ab-2; GM-Tg-equg-IP2909-Ab-1/ GM-Tg-equg-IP2909-Ab-2
Products Name SETD1B protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name SETD1B
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine SETD1B protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.